Chronic Toxicity After Adjuvant Anti-PD-1 in Melanoma Under Scrutiny
Melanoma survivors treated with adjuvant anti-PD-1 face persistent immune-related toxicities; Andrea Boutros examines the long-term burden in Oncodaily.
Topic
Topic
Melanoma survivors treated with adjuvant anti-PD-1 face persistent immune-related toxicities; Andrea Boutros examines the long-term burden in Oncodaily.